This Swiss cannabis company that specializes in high-quality medical cannabis flowers and extracts, is looking for a strategic equity partner for their cultivation and processing facility. This company is on track to become a key leader in the European market, targeting Germany, Austria, Switzerland, and other global regions.
Business Highlights:
State-of-the-Art Facility:
- Operating from a custom-built, 10,000 m² leased facility with 25 grow rooms, advanced chemistry and biology labs, and a GMP-certified cleanroom for microbiological testing.
- More than CHF 60-70 million has been invested in developing the facility.
Production & Revenue:
- The initial production phase has already secured CHF 7 million in contracts.
- Full-scale production is set to begin in Q1 2025, with projected revenue reaching CHF 40 million and targeting CHF 70 million by 2026, driven by cannabis extraction and branded product launches.
Market Reach:
- Strategically positioned to lead the DACH region (Germany, Austria, Switzerland) and expand globally.
- Prioritizing R&D, sustainability, and the promotion of cannabis-based health benefits to build trust and achieve market leadership.
Strategic Agreements:
- Initial offtake agreements secured, ensuring efficient and reliable production and distribution.
- Annual production capacity of 18 tons, with plans to finalize additional agreements to fully utilize this capacity.
Expert Team:
- Industry-leading international team with deep expertise in global medical cannabis markets.
Investment Opportunity:
- Seeking CHF 6 million in equity investment for a 20% stake to fund the launch of the GMP-certified indoor production facility.
- Open to bridge loan finance, M&A opportunities, or full divestiture.
With an advanced facility, secured contracts, and ambitious growth targets, this Swiss medical cannabis leader presents a unique opportunity to partner in the rapidly expanding European market, poised to set new industry standards.
